Eurekam Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$6.34M
- Investors
-
7
Eurekam General Information
Description
Developer of artificial intelligence-based image technologies designed to offer the process of controlled drug protection. The company's technologies help to reach verified and archived preparations, avoid posterior sampling errors and double visual inspection, reduce medication errors and protect from legal risks, enabling the healthcare sector to get a response that matches the regulatory requirements.
Contact Information
Website
www.eurekam.frCorporate Office
- 4 Rue Louis Tardy
- 17140 Lagord
- France
Corporate Office
- 4 Rue Louis Tardy
- 17140 Lagord
- France
Eurekam Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 05-Oct-2022 | $6.34M | Completed | Generating Revenue | ||
| 3. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 2. Later Stage VC | 04-Apr-2018 | $1.85M | $2.5M | Completed | Generating Revenue | |
| 1. Early Stage VC | 23-Jul-2013 | $652K | $652K | Completed | Generating Revenue |
Eurekam Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| ADP A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Eurekam Patents
Eurekam Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3797511-A1 | Device and method for recognising a label deposited on an object in order to securely produce drug preparations | Active | 22-May-2018 | ||
| EP-3797511-B1 | Device and method for recognising a label deposited on an object in order to securely produce drug preparations | Active | 22-May-2018 | ||
| WO-2019224438-A1 | Device and method for recognising a label deposited on an object in order to securely produce drug preparations | Inactive | 22-May-2018 | ||
| FR-3081584-A1 | Device and method for recognizing a label deposited on an object for secure preparation of medicinal products | Active | 22-May-2018 | ||
| FR-3081584-B1 | Device and method for recognizing a label deposited on an object for the secure preparation of drug preparations | Active | 22-May-2018 | B25J21/02 |
Eurekam Signals
Eurekam Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Impact Partners (Paris) | Impact Investing | Minority | ||
| Aquiti | PE/Buyout | Minority | ||
| Région Nouvelle-Aquitaine | Government | Minority | ||
| Sofimac Innovation | Venture Capital | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority |
Eurekam FAQs
-
When was Eurekam founded?
Eurekam was founded in 2012.
-
Where is Eurekam headquartered?
Eurekam is headquartered in Lagord, France.
-
What is the size of Eurekam?
Eurekam has 27 total employees.
-
What industry is Eurekam in?
Eurekam’s primary industry is Outcome Management (Healthcare).
-
Is Eurekam a private or public company?
Eurekam is a Private company.
-
What is Eurekam’s current revenue?
The current revenue for Eurekam is .
-
How much funding has Eurekam raised over time?
Eurekam has raised $8.84M.
-
Who are Eurekam’s investors?
Impact Partners (Paris), Aquiti, Région Nouvelle-Aquitaine, Sofimac Innovation, and Bpifrance are 5 of 7 investors who have invested in Eurekam.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process